What question did this study set out to answer?

This research aims to evaluate the prognostic performance of a genomic risk test in early-stage hormone-receptor positive breast cancer patients.

May 24, 2026Open Access

66P Prognostic performance of a novel genomic risk test in patients with early-stage hormone-receptor positive breast cancer: A TransATAC study

Key Points

This research aims to evaluate the prognostic performance of a genomic risk test in early-stage hormone-receptor positive breast cancer patients.
TransATAC study design
Inclusion of patients with T1N0 early-stage breast cancer
Analysis of 3-year recurrence-free survival rates based on MammaPrint risk group.
Patients with H2 tumors identified by MammaPrint had significantly worse outcomes compared to H1 and LR/UL cancers, with specific event rates noted.
Overall, 10% of all patients and 5% with HR+HER2 tumors experienced adverse outcomes.
Findings suggest that some T1N0 patients may need escalated therapy and biology-informed treatment approaches.

Abstract

Table: 65P Prognostic Performance of MammaPrint for Recurrence-Free Survival Patients with T1a,b,c N0 breast cancer MP Risk Group 3-Year RFS % (95% CI) pvalue Multivariable HR (95% CI)Conclusions: Among this cohort of pts with clinically early-stage (T1N0 EBC), MP identified pts with H2 tumors (10% overall and 5% among pts with HR+HER2disease) who experienced significantly worse outcomes compared with those with H1 and LR/UL cancers.These findings highlight the prognostic value of MP in clinically small EBC and indicate that a subset of pts with T1N0 may benefit from escalated therapy and biology-informed treatment approaches.Clinical trial identification: NCT03053193.

Perguntar à IA

Bookmark

View Full Paper